Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biontech Se ADR
(NQ:
BNTX
)
88.22
+0.62 (+0.71%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biontech Se ADR
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
63
64
Next >
Stocks Ready For A Bounce
July 07, 2022
The past few days have been volatile, but, stocks look ready for a bounce. Since the last CPI report, even energy stocks have fallen, pretty sharply in fact.
Via
Talk Markets
Drugmakers, Health Authorities Discarding Several Million COVID-19 Vaccine Doses: Report
July 06, 2022
Via
Benzinga
5 Analysts Have This to Say About BioNTech
July 06, 2022
BioNTech (NASDAQ:BNTX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
July 06, 2022
The company isn't seeking an injunction, but wants "fair compensation."
Via
Investor's Business Daily
Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit?
July 05, 2022
The FDA's advisors recently backed Pfizer's Covid shot for young children.
Via
Investor's Business Daily
Is Moderna Stock A Buy As The Covid Battle With Pfizer Heats Up?
July 05, 2022
Moderna and Pfizer are likely to launch their Covid vaccines for babies at the same time.
Via
Investor's Business Daily
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
July 05, 2022
The company isn't seeking an injunction, but wants "fair compensation."
Via
Investor's Business Daily
CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech
July 05, 2022
Via
Benzinga
7 Best Healthcare Stocks to Buy Now
July 04, 2022
The move toward treating DNA as akin to a programming language is just getting started, but you can start profiting on healthcare stocks now.
Via
InvestorPlace
FDA Expert Panel Favors COVID-19 Boosters Targeting Omicron BA.4, BA.5 Subvariants
July 01, 2022
Via
Benzinga
Why BioNTech Stock Is Surging
June 30, 2022
BioNTech SE (NASDAQ: BNTX) shares are trading higher Thursday after the company and Pfizer Inc (NYSE: PFE) announced a new COVID-19 vaccine supply agreement with the U.S. government.
Via
Benzinga
Why Pfizer Stock Is Rising Today
June 30, 2022
Pfizer Inc (NYSE: PFE) shares are trading higher Thursday after the company and BioNTech SE (NASDAQ: BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government.
Via
Benzinga
This Analyst Says US Government Buying More COVID-19 Vaccines At Higher Prices
June 30, 2022
Via
Benzinga
PFE Stock Rises as Pfizer Requests FDA Approval of Covid-19 Treatment Paxlovid
June 30, 2022
PFE stock is up in afternoon trading as Pfizer enjoys a double round of positive news regarding its Covid-19 drugs.
Via
InvestorPlace
The FDA Just Handed BioNTech And Moderna A Gift — But Only One Jumped
June 30, 2022
The request is a boon for BioNTech and Moderna, both of which are facing a sales cliff.
Via
Investor's Business Daily
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
June 30, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga Before The Bell: Texas Giga Tesla's Output Ramp Up, California's Lithium Tax, Spot Bitcoin ETF Proposal Rejection And Other Top Financial Stories Thursday, June 30
June 30, 2022
Reuters Hyundai, Affiliates Plan To Set Up New Company In US:
Via
Benzinga
US Government Calls For Additional Doses Of Pfizer/BioNTech COVID-19 Vaccine
June 30, 2022
Via
Benzinga
Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
June 29, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer, Moderna Analysts Respond To FDA COVID Booster Ruling: 'Revenues Will Decline'
June 29, 2022
The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news,...
Via
Benzinga
Novavax Stock Is in Prime Position For Speculation
June 29, 2022
NVAX stock is on the cusp of the FDA approval that has long eluded the firm, meaning now is the best time to speculate on Novavax.
Via
InvestorPlace
Pfizer, Moderna, Novavax Tumble As FDA Experts Consider Omicron Shots
June 28, 2022
A panel of experts will decide whether to recommend omicron-specific boosters.
Via
Investor's Business Daily
US Government Offers $75M Support For Lipid Systems Expansion Used In mRNA COVID-19 Vaccines
June 28, 2022
Via
Benzinga
Why Pfizer Partner BioNTech Shares Are Rising Today
June 27, 2022
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 6.31% at $142.50 after the company announced its Omicron-adapted COVID-19 vaccine candidates demonstrated high immune response against the...
Via
Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
June 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Pfizer/BioNTech's Updated Omicron-Based COVID-19 Shots Show Improved Response Against Variant
June 27, 2022
Via
Benzinga
7 Biotech Stocks With Key Catalysts Coming in July
June 27, 2022
Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth.
Via
InvestorPlace
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
June 25, 2022
From
Pfizer Inc.
Via
Business Wire
The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial
June 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
BioNTech Gets EMA's Priority Medicines Status For Testicular Cancer Drug
June 23, 2022
BioNTech (NASDAQ: BNTX) received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for its product candidate BNT211 in the third- or later-line treatment of testicular...
Via
Benzinga
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
63
64
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.